LIXTE BIOTECHNOLOGY HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $200.0K | Mar 28, 2016 |
| FY2013 | Dec 31, 2013 | $0 | Mar 21, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 21, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Mar 15, 2013 |
| FY2011 | Dec 31, 2010 | $0 | Mar 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.59M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($5.09M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($6.31M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($6.73M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($3.26M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($2.44M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($2.13M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.81M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($2.13M) | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.11M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.57M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($5.09M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($6.31M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($6.72M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($3.27M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($2.49M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($2.14M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.81M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($2.13M) | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $254.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $726.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $898.1K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.35M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.74M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.22M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $820.9K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $40.7K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $467.3K | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $870.0K | Mar 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.16M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.29M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($4.61M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($4.14M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($2.13M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $1.67M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($1.51M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.41M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($1.68M) | Mar 23, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.15M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.31M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $5.56M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $5.09M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.23M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $2.67M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $4.34M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.37M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $433.4K | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $318.3K | Mar 31, 2026 |
| FY2016 | Dec 31, 2016 | $218.7K | Mar 29, 2017 |
| FY2014 | Dec 31, 2014 | $273.4K | Mar 27, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $827.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.99M | Mar 24, 2025 |
| FY2024 | Dec 31, 2022 | $5.17M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $4.79M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $5.01M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $2.43M | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | $4.13M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $995.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $214.8K | Mar 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($52.07M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($48.48M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($43.39M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($37.08M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($30.35M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($27.09M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($24.65M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($22.52M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($20.71M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.20M | Mar 19, 2024 |
| FY2023 | Dec 31, 2022 | $5.35M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.82M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.07M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $2.60M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $4.27M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.31M | Mar 25, 2019 |
| FY2018 | Dec 31, 2016 | $199.9K | Mar 25, 2019 |
| FY2017 | Dec 31, 2015 | $25.3K | Mar 23, 2018 |
| FY2016 | Dec 31, 2014 | $44.4K | Mar 29, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | (2) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 19, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.79M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2.25M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 1.66M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 13.75M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 12.40M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 11.17M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 67.05M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 58.03M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | 47.88M | Mar 23, 2018 |